CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (SORADOX trial): interim results of a prospective, randomized, open-label, multicenter phase IIB trial (NCT01272557)
DOI 10.1055/s-0034-1386203
Bibliografische Angaben
Nachweis in CareLit
Autor:innenTJ Ettrich, S Behl, AW Berger, A Zipprich, DT Waldschmidt, MA Wörns, S Belle, P Michl, T Seufferlein, MM Dollinger
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Sorafenib is currently regarded as standard of care in patients with hepatocellular carcinoma BCLC stage C. Recent results of a Phase II study with Doxorubicin +/- Sorafenib investigating time to progression (TTP) and overall survival (OS) demonstrated an increased OS of 3 months in the combination arm as compared with Sorafenib alone in the original Sharp trial. Aim: To assess efficacy and safety of t…
Zitieren
Zitierempfehlung
TJ Ettrich, S Behl, AW Berger, A Zipprich, DT Waldschmidt, MA Wörns, S Belle, P Michl, T Seufferlein, MM Dollinger (2014) Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (SORADOX trial): interim results of a prospective, randomized, open-label, multicenter phase IIB trial (NCT01272557). Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0034-1386203
Mit CareLit weiterarbeiten